RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

Yet another point we've already hammered into the ground. I'll repeat it one more time: when CX717 was on clinical hold, and the outcome of the preclinical testing was yet to be established, no solid CMO was going to join the company. Mansbach left partly because he wasn't sure there'd be a clinical program to oversee. The fact that Tran joined, and he could have backed out after the IND was rejected, indicates that he sees a reason to be at Cortex. That certainly doesnt guarantee success, but indicates no smoking gun arguing against it.

<<He's some French guy who likes food. >>

Why does the insightfulness of your posts oscillate more dramatically than my fourteen year old daughter's hormone levels?

You can do better than that.

NeuroInvestment